Trends in neutropenia-related inpatient events

Journal of Oncology Practice

Volumn 8, Issue 3, 2012, Pages 149-155

  Kozma, Chris M ^a   Dickson, Michael ^a   Chia, Victoria ^a   Legg, Jason ^a   Barron, Richard ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IRINOTECAN; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; DRUG USE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PREVALENCE;

EID: 84867918759     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000360     Document Type: Article

References (23)

1. Lyman GH, Lyman CH, Agboola O: Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427-437, 2005 (Pubitemid 40993570)
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, Version 1.2011. Fort Washington, PA, National Comprehensive Cancer Network, 2011
3. Agency for Healthcare Research and Quality: HCUP Nationwide Inpatient Sample: Healthcare Cost and Utilization Project (HCUP). 1989-2007. Rockville, MD, Agency for Healthcare Research and Quality, 2009
4. WHO Collaborating Centre for Drug Statistics Methodology: International Language for Drug Utilization Research: Anatomical Therapeutic Chemical (ATC) and Define Daily Dose (DDD) Classification System. www.whocc.no/
5. Caggiano V, Weiss RV, Rickert TS, et al: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916-1924, 2005 (Pubitemid 40563265)
6. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006 (Pubitemid 43673249)
7. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas Version 2.2011. Fort Washington, PA, National Comprehensive Cancer Network, 2011
8. Norton L: Conceptual and practical implications of breast tissue geometry: Toward a more effective, less toxic therapy. Oncologist 10:370-381, 2005
9. Shayne M, Culakova E, Wolff D, et al: Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 115: 5319-5328, 2009
10. Lyman GH: Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7:99-108, 2009
11. Markman M: Managing taxane toxicities. Support Care Cancer 11:144-147, 2003
12. Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25: 3158-3167, 2007 (Pubitemid 47218066)
13. Lyman GH, Dale DC, Wolff DA, et al: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. J Clin Oncol 28:2914-2924, 2010
14. Lyman GH, Michels SL, Reynolds MW, et al: Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555-5563, 2010
15. Chen-Hardee S, Chrischilles EA, Voelker MD, et al: Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 17:647-654, 2006 (Pubitemid 43668322)
16. Eldar-Lissai A, Cosler LE, Culakova E, et al: Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11:172-179, 2008 (Pubitemid 351473616)
17. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23: 1178-1184, 2005 (Pubitemid 46202274)
18. Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453, 2006 (Pubitemid 44442936)
19. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 100:228-237, 2004 (Pubitemid 38063629)
20. Lyman GH: Prediction and prevention of neutropenic complications in older patients receiving cancer chemotherapy. Am Soc Clin Oncol Ed Book 191-196, 2011
21. Kieseier BC, Jeffery DR: Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord 3:277-291, 2010
22. Yildirim-Toruner C, Diamond B: Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127:303-312; quiz 313-314, 2011
23. Horner MJ, Ries LAG, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2006. Bethesda, MD, National Cancer Institute, 2009